title: Design, conduct, and interpretation of organ impairment studies in oncology patients.
authors.forename: Chris H
authors.initials: CH
authors.lastname: Takimoto
authors.forename: Alain C
authors.initials: AC
authors.lastname: Mita
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic / Q000592:standards; D019587:Dietary Supplements; D004334:Drug Administration Schedule; D005492:Folic Acid / Q000008:administration & dosage*; D005493:Folic Acid Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D005971:Glutamates / Q000008:administration & dosage / Q000009:adverse effects*; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D000068437:Pemetrexed; D012107:Research Design
chemical_list: D000964:Antimetabolites, Antineoplastic; D005493:Folic Acid Antagonists; D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D005492:Folic Acid